Founded by Dr. Shu Xiaozheng on April 28, 2008, who is a well-known scientist trained in the U.S., BIOREGEN is a high-tech company with independent R&D capabilities based on the technology platform of Advanced Self-Crosslinked & Biomimetic Biomaterials, deeply cultivate the fields of clinical medicine and biomedicine.
BIOREGEN is committed to becoming a leader of novel biomedical materials for wound repair in both domestic and overseas markets. The company mainly engages in R&D, production and sales of novel biomedical materials as well as drug sustained release agents. We aim to solve medical difficulties in the specialties of ENT, GYN, general surgery etc. and meet the needs of clinical departments.
With a beautiful vision and noble mission: rejuvenating the injured tissue. The company has developed a range of postoperative functional healing materials for ENT, GYN, etc., and has successfully entered the medical markets in the United States, Germany, UK, France, Italy and other developed countries.
Founded on April 28, 2008
Total number of employees
Business footprint in more than 50 countries
Dr. Shu Xiaozheng, the founder and chairman of the company, is a world-renowned scientist in biomedical materials and regenerative medicine. He has been dedicated to cutting-edge biomedical research for more than 20 years. From 1992 to 2001, Dr. Shu studied at Zhejiang University and obtained a doctorate degree in chemistry. From 2001 to 2006, he conducted postdoctoral research and served as a research faculty member at University of Utah. During this period, he got involved in more than ten research projects of the National Institutes of Health and the National Science Foundation. With his research results, three high-tech startups were founded. In 2006, Dr. Shu returned to China and set up the entrepreneurial team of BioRegen Biomedical to lead the R&D and industrialization of innovative products.
2008The scientist who studied abroad was rated as a provincial talent of entrepreneurship and innovation;
2009The first company in Changzhou to pass the new GMP certification for medical devices;
2010Passed the quality management system for the ENT product “PureRegen Gel”,
2011Launched the Class II ENT product and set up the Beijing office. 2011
2012Launched the product for intrauterine cavity “MateRegen Gel” in overseas markets. 2012
2013Launched the Class III ENT product,
2015Launched the Class II product for intrauterine cavity,
2016Established the Shanghai Branch,
2017Moved to the new factory for expanding the production scale to meet the market demand;
2018Reached the tenth anniversary with steady progress through trials and hardships. 2018
2019Established the Sino-EU academic exchange platform and successfully held the Sino-EU seminars;
2021Launched the independent brand "VitRegen";
2022The company’s pelvic cavity product was approved by CFDA as Class III medical device;
2023The company completes the stock restructuring;